Amicus Therapeutics (FOLD) Stock Price

Amicus Therapeutics Price

NASDAQ·CLOSED
14.49
​
Market closed

Over the last 18 years Amicus Therapeutics grew revenue by 38.6% annually, reaching 634.21 M USD. For Amicus Therapeutics, the net margin of -4.3% is up versus -82.0% a few years ago. The consensus 12-month price target for Amicus Therapeutics is 14.79 USD, about 2.1% above where the stock trades today. Of 14 analysts, 6 rate the stock a buy — an overall Hold consensus.

Amicus Therapeutics stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Amicus Therapeutics business model & stock analysis

Amicus Therapeutics Inc. is a biopharmaceutical company specializing in the development of drugs for the treatment of rare diseases. The company was founded in 2002 and is headquartered in Cranbury, New Jersey.

Frequently asked questions about Amicus Therapeutics

The business model of Amicus Therapeutics Inc. revolves around developing advanced therapies for rare and orphan diseases. The company focuses on utilizing its Chaperone-Advanced Replacement Therapy (CHART™) platform to deliver enzyme replacement therapies (ERTs) for individuals suffering from lysosomal storage disorders (LSDs). As a biopharmaceutical company, Amicus Therapeutics aims to address unmet medical needs through innovative drug research and development. By leveraging their expertise in protein misfolding and folding, Amicus Therapeutics aims to improve the lives of patients with genetic diseases.

Amicus Therapeutics Inc is primarily active in the biotechnology industry.

The main competitors of Amicus Therapeutics Inc in the market include companies such as Vertex Pharmaceuticals, BioMarin Pharmaceutical, and Sanofi Genzyme.

Amicus Therapeutics Inc is a biopharmaceutical company headquartered in Cranbury, New Jersey. Founded in 2002, Amicus Therapeutics focuses on developing advanced therapies for rare and orphan diseases. The company's innovative approach is based on the principles of personalized medicine, utilizing breakthrough science and technology. Over the years, Amicus Therapeutics has established itself as a leader in the field, with a strong dedication to improving the lives of patients with devastating genetic diseases. Through its robust research and development efforts, Amicus Therapeutics has successfully advanced several potential treatments, striving to bring hope and transformative therapies to those in need.

Amicus Therapeutics Inc has achieved significant milestones in its journey. Some notable accomplishments include the approval of Galafold, a breakthrough therapy for Fabry disease, by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Additionally, the company has made remarkable progress in developing innovative therapies for rare genetic diseases such as Pompe disease and other lysosomal storage disorders. Amicus Therapeutics Inc has successfully conducted clinical trials and obtained positive results, showcasing their commitment to advancing medical science and improving patients' lives. Their unwavering dedication has positioned them as a leading player in the biopharmaceutical industry.

Amicus Therapeutics Inc is primarily present in the United States.

Amicus Therapeutics Inc represents values of innovation, dedication, and patient-centricity. With a corporate philosophy focused on delivering life-changing therapies, Amicus strives to improve the lives of individuals with rare and devastating diseases. The company is committed to advancing science, developing transformative medicines, and ensuring access to those therapies for patients in need. Amicus fosters a collaborative and compassionate approach, working closely with patient advocacy groups, healthcare professionals, and regulatory authorities to make a meaningful impact in the lives of the communities it serves.

Analysts currently set an average price target of 15.81 USD for the Amicus Therapeutics stock (median: 14.79 USD), implying +9.1 % versus the latest price. The consensus is based on 14 analyst ratings.

14 analysts currently rate the Amicus Therapeutics stock: 6 recommend buying, 8 holding and 0 selling. For 2026, analysts expect Amicus Therapeutics to generate revenue of 753.69 M USD and earnings per share of 0.36 USD.

Converted at the current exchange rate, the Amicus Therapeutics share trades at 13.20 EUR (14.49 USD).

The Amicus Therapeutics share (FOLD) is listed on 6 stock exchanges, including: NASDAQ (FOLD), London (0HF9.L), Frankfurt (AM6.F), München (AM6.MU), Düsseldorf (AM6.DU).

Amicus Therapeutics Inc (Nasdaq: FOLD) aims to develop and manufacture novel therapies for people with rare and severe diseases. The biotechnology company, based in Cranbury, New Jersey, USA, focuses on researching and developing drugs that aim to influence the natural metabolism of proteins in the body to treat diseases caused by mutations in genes. The business model of Amicus Therapeutics is based on the discovery and development of therapies specialized in treating rare and severe diseases. The company works closely with patients and their families to gain a better understanding of the needs and challenges of these patient groups. Amicus utilizes a proprietary technology platform called Chaperon-Advanced Replacement Therapy (CHART), which allows for the treatment of Ectopic Glycosylation Disorders (EGS) by replacing faulty proteins produced by gene mutations with functional and stable therapeutics. Amicus Therapeutics specializes in the following three areas: 1. Fabry disease: A rare lysosomal metabolic disorder where the Alpha-Galactosidase-A enzyme is not produced normally due to mutations in the GLA gene. Amicus has developed Galafold, the first oral medication for treating Fabry disease, which aims to stabilize the faulty protein. 2. Pompe disease: A lysosomal storage disease characterized by a deficiency of enzymes that help in breaking down glycogen. This results in an accumulation of glycogen in various tissues and organs. Amicus has developed ATB200/AT2221, a combined therapy of enzyme replacement therapy and chaperone therapy aimed at correcting the enzyme deficiency caused by mutation. 3. Phenylketonuria (PKU): A metabolic disorder where an individual lacks the ability to metabolize phenylalanine. This leads to an accumulation of phenylalanine in the body, which can cause impairments to the central nervous system. Amicus has a pipeline of therapeutics in development for treating PKU, including a chaperone platform and an enzyme replacement therapy. Amicus Therapeutics collaborates closely with medical centers, patient organizations, and research institutions to develop innovative therapies for rare and severe diseases. The company is committed to enhancing the effectiveness and safety of medications, helping to improve the quality of life for affected individuals. By focusing on rare and severe diseases, Amicus Therapeutics can serve a niche and position itself as an innovator in the biotechnology industry. Overall, Amicus Therapeutics' business model has the potential to achieve significant medical advancements while also being profitable. The company is well-positioned to continue developing innovative therapies for rare and severe diseases that can improve the lives of patients and their families.

The expected revenue of Amicus Therapeutics is 753.69 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Amicus Therapeutics is 111.97 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Amicus Therapeutics is currently 40.68. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Amicus Therapeutics stock.

The price-to-sales ratio (P/S) of Amicus Therapeutics is currently 6.04. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Amicus Therapeutics stock.

The Eulerpool Quality Score for Amicus Therapeutics is 4/10.

The ISIN of Amicus Therapeutics is US03152W1099. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Amicus Therapeutics is A0MSMZ. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Amicus Therapeutics is FOLD. The ticker symbol is used to trade Amicus Therapeutics shares on the stock exchange.

Fair ValueTerminal
12.32 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
1.24 M USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website amicusrx.com
Currency
USD
Initial public offering
May 31, 2007
ISIN
US03152W1099
Cusip
03152W109
Sedol
B19FQ48
Market capitalization
4.55 B USDMid Cap
52-Week Range
PEG
-4.64
P/E ratio
P/Ee 2026
40.63
P/Ee 2027
22.64
P/Ee 2028
15.92
P/Ee 2029
10.65
P/Ee 2030
8.68
P/S
P/Se
6.04
EV/EBIT
137.31
P/B Ratio
16.59
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-4.01 %
Last updated Nov 19, 2026, 10:18 PM

Amicus Therapeutics Ticker

DÜSSELDORF · AM6.DUFRANKFURT · AM6.FLONDON · 0HF9.LLONDON STOCK EXCHANGE · 0HF9.LMUNICH · AM6.MUNASDAQ · FOLD

Amicus Therapeutics FIGI

AM6:GR · BBG000F0TV39AM6:GF · BBG000F0TVG5AM6:GD · BBG000F0TVT1AM6:GS · BBG000F0VYF7AM6:GM · BBG000F0VZ55AM6:GB · BBG000F0VZK8FOLD:US · BBG000PLF6N0FOLD:UA · BBG000PLF7J3FOLD:UC · BBG000PLF7M9FOLD:UN · BBG000PLF810FOLD:UP · BBG000PLF8J1FOLD:UQ · BBG000PLF8M7

All fundamentals and in-depth analysis of Amicus Therapeutics

Our stock analysis for Amicus Therapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Amicus Therapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.